Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.

ABSTRACT:

Background

Childhood obesity is a major public health concern with limited treatment options.

Objective

The aim of this study was to assess safety, tolerability, pharmacokinetics, and pharmacodynamics during short-term treatment with liraglutide in children (7-11 y) with obesity.

Methods

In this randomized, double-blind, placebo-controlled trial, 24 children received at least one dose of once-daily subcutaneous liraglutide (n = 16) or placebo (n = 8) starting at 0.3 mg with weekly dose escalations up to 3.0 mg or maximum tolerated dose, and 20 children completed the trial (14 in the liraglutide group and six in the placebo group). The primary endpoint was the number of adverse events.

Results

Baseline characteristics (mean ± standard deviation) included the fol

SUBMITTER: Mastrandrea LD 

PROVIDER: S-EPMC6590663 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature